Hagiwara et al. found that EPA inhibits phosphorylation of ERK1/2 in the glomeruli, reduces mesangial ECM and tubulointerstitial fibrosis, and decreases hypertriglyceridemia and other CVD risk factors in a mouse model of diabetic nephropathy [143]. The gene discussed is MAPK3; the disease is diabetic kidney disease.